CARMEL,

NeurAxis Announces New Medical Policy Coverage in North Dakota

Retrieved on: 
Tuesday, April 23, 2024
Irritable bowel syndrome, FDA, BCBS, Neuraxis, Ear, Abdominal pain, IBS, Health insurance

CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota.

Key Points: 
  • CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota.
  • The BCBS licensee is the largest provider of health care coverage in North Dakota, insuring and/or administering claims for over 310,000 people, effective May 6, 2024.
  • Neuraxis’ PENFS technology is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old.
  • “We are pleased to announce a new medical coverage policy, expanding our total covered lives for IB-Stim™ to approximately 16.5 million individuals, which speaks to the strength of the clinical data,” said Brian Carrico, President and Chief Executive Officer of NeurAxis.

NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, April 9, 2024
Neuraxis, BCBS, Abdominal pain, Patient, API, Health insurance

Gross profit margin in the fourth quarter of 2023 was 86.4%, compared to 87.7% for the same period in 2022.

Key Points: 
  • Gross profit margin in the fourth quarter of 2023 was 86.4%, compared to 87.7% for the same period in 2022.
  • Selling expenses for fiscal year 2023 were $323.6 thousand, a decrease of 21.3% compared to $410.9 thousand for fiscal year 2022.
  • Selling expenses for the fourth quarter of 2023 were $72.6 thousand, an increase of 10.1% compared to $66.0 thousand for the fourth quarter of 2022.
  • G&A costs for the fourth quarter of 2023 were $2.0 million, an increase of 46.1%, compared to $1.4 million for the fourth quarter of 2022.

NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

Retrieved on: 
Monday, April 1, 2024
Neuraxis, Form, PIN, Webcast, Calendar, Form 10-K, IPO

The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 pm ET to review the results.

Key Points: 
  • The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 pm ET to review the results.
  • Call-in Information: Interested parties can also access the live conference call by initially registering at the following link .
  • As indicated in this press release, the Company expects to have filed its Form 10-K on April 9, 2024.
  • The Company is unable to file timely due primarily to the unique circumstances associated with the Company’s IPO last year.

NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry

Retrieved on: 
Wednesday, March 27, 2024
Neuraxis, Abdominal pain, Patient, API, Pain

IB-Stim is NeurAxis’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy.

Key Points: 
  • IB-Stim is NeurAxis’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy.
  • The large and comprehensive study concluded efficacy of IB-Stim for gastrointestinal symptoms and functionality for pediatric disorders of gut-brain interaction (DGBI).
  • Dr. Adrian Miranda, Chief Medical Officer of NeurAxis stated, “To my knowledge, this is the largest, prospective, multicenter registry for any drug or device in pediatric patients with pain associated DGBIs.
  • The results significantly highlight the durability of response after just 4 weeks of treatment, which is a commonly asked question.

NeurAxis Announces Highmark BCBS Policy Coverage

Retrieved on: 
Monday, March 11, 2024
Neuraxis, Highmark, Policy

CARMEL, Ind., March 11, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Highmark Blue Cross Blue Shield (“Highmark BCBS”) policy coverage for approximately seven million lives effective April 8, 2024.

Key Points: 
  • CARMEL, Ind., March 11, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Highmark Blue Cross Blue Shield (“Highmark BCBS”) policy coverage for approximately seven million lives effective April 8, 2024.
  • Highmark BCBS provides coverage in the mid-Atlantic, covering Pennsylvania, Delaware, New York, and West Virginia.
  • “We are thrilled to announce new policy coverage from Highmark BCBS, expanding our total covered lives to now approximately 16.25 million individuals,” said Brian Carrico, President and Chief Executive Officer of NeurAxis.
  • We look forward to receiving positive responses from payers on a national level as we aim to expand the coverage of IB-Stim.”

NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage

Retrieved on: 
Monday, March 4, 2024
Neuraxis, Blue Shield, Blue Cross, Policy, Health insurance

CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Blue Cross and Blue Shield of Kansas City (“BCBSKC”) policy coverage for approximately one million lives.

Key Points: 
  • CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Blue Cross and Blue Shield of Kansas City (“BCBSKC”) policy coverage for approximately one million lives.
  • BCBSKC provides coverage in the Kansas City, Missouri metropolitan areas including Johnson and Wyandotte counties in Kansas.
  • “We are happy to announce new policy coverage from BCBSKC, expanding our total covered lives to now approximately 9.25 million individuals,” said Brian Carrico, President and Chief Executive Officer of NeurAxis.
  • “We remain focused on executing on our commercial strategy, leveraging clinical evidence supporting IB-Stim to obtain payer coverage and then driving market adoption of our technology.

NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Retrieved on: 
Tuesday, February 27, 2024
Neuraxis, Webcast, Medtech, Conference

CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will participate in the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.

Key Points: 
  • CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will participate in the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.
  • NeurAxis will give a corporate presentation on Tuesday, March 12, 2024, at 8:40 am ET and host investor 1x1 meetings, which can be requested through Oppenheimer.
  • To access the live webcast, please visit the investors page of the NeurAxis website.
  • The webcast will also be available for replay on NeurAxis’ investor relations website.

NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

Retrieved on: 
Wednesday, January 31, 2024
Follett Corporation, Growth, CFO, General Electric, Anesthesiology, Neuraxis, Certified Public Accountant, Ernst & Young, Executive, Education, University, Software, Federal Signal Corporation, Health, Management

CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024.

Key Points: 
  • CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024.
  • "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis,” said Brian Carrico, President and Chief Executive Officer of NeurAxis.
  • Most recently, Mr. Henrichs served as the Chief Financial Officer of Renovo Home Partners since 2022.
  • “I am excited to be joining NeurAxis as its Chief Financial Officer,” said Tim Henrichs.

NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer

Retrieved on: 
Wednesday, December 20, 2023
Policy, Indigestion, Neuraxis, FDA, Medical classification, RED, University, Insurance, Letter, IPO, Constipation, Publication, CareFirst BlueCross BlueShield

As we look back at the first 120 days since our IPO, we are very pleased with our accomplishments.

Key Points: 
  • As we look back at the first 120 days since our IPO, we are very pleased with our accomplishments.
  • Highly successful med-tech companies build success from the foundation of strong data publications, which leads to broad insurance policy coverage which results in exponential revenue growth.
  • The primary goal in the 4th quarter was to make sure the publications were in place to confidently ask insurance companies for written policy coverage, and we have succeeded.
  • We have now executed and delivered one of the strongest med-tech research publication portfolios in the industry.

NeurAxis Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 20, 2023
Policy, Adolescence, Research, Neuraxis, Percutaneous, Hospital, Record, Abdominal pain, RED, Disability, University, Cyproheptadine, Growth, Publication, Patient, CareFirst BlueCross BlueShield, Amitriptyline, FAPD, Video game

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.
  • Gross margin totaled 85.9% in the third quarter of 2023, compared to 89.1% in the third quarter of 2022.
  • Selling expenses for the third quarter of 2023 were $64.2 thousand, compared to $81.6 thousand in the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $3,323.4 thousand, compared to $1,586.5 thousand in the third quarter of 2022.